Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Antonio Rivero, Sociedad Andaluza de Enfermedades Infecciosas
ClinicalTrials.gov Identifier:
NCT01006031
First received: October 29, 2009
Last updated: December 28, 2011
Last verified: December 2011

October 29, 2009
December 28, 2011
October 2009
December 2011   (final data collection date for primary outcome measure)
Sustained viral response (undetectable serum HCV-RNA) [ Time Frame: Throughout treatment and 24 weeks after finishing it ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01006031 on ClinicalTrials.gov Archive Site
  • Relationships between the plasma interferon an ribavirin concentrations and efficacy [ Time Frame: Throughout treatment and 24 weeks after finishing it. ] [ Designated as safety issue: No ]
  • safety and tolerability of the studied medications [ Time Frame: Throughout treatment and 24 weeks after finishing it ] [ Designated as safety issue: Yes ]
  • The evolution of liver fibrosis will be evaluated comparing the basal and end of treatment results of transient elastometry [ Time Frame: baseline and after finishing treatment ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4
Efficacy of High Doses of Both Pegylated Interferon Alfa-2a and Ribavirin for Retreatment of HIV-coinfected Patients With Liver Cirrhosis Due to HCV Genotype 1 or 4 Nonresponders to Previous Standard Therapy.

Objective: To evaluate the efficacy and safety of high doses of both peginterferon-alfa 2a (360 ug per week) plus ribavirin (800 mg b.i.d.) in HIV-infected patients with compensated liver cirrhosis by HCV genotype 1 or 4 without previous virological response(*) to a standard dose treatment of both drugs.

(*) Non previous virological response: no decrease of plasma RNA-HCV at least 2 log10 after 12 weeks in treatment or breakthrough viremia while on treatment.

Additionally, this study will evaluated the influence of simultaneous peginterferon-alfa 2a and ribavirin plasma concentrations on early viral response (EVR) and sustained viral response (SVR) in these patients.

Method: Pilot clinical trial, phase II-III, open labeled multicenter in which patients from several hospitals of the Servicio Andaluz de Salud will be enrolled.

The usual clinical and analytical follow up will be performed but additional blood samples will be obtained for determination of interferon and ribavirin plasma levels. The primary end point will be a sustained virologic response (defined as an undetectable serum HCV-RNA after 24 weeks after the cessation of treatment). Likewise, rapid virological response (at 4 weeks of treatment), early virological response (at 12 weeks), and end of treatment response rates will be evaluated as well as their relationships with the plasma interferon an ribavirin concentrations determined by ELISA and HPLC, respectively. The safety and tolerability of the studied medications will be evaluated by means of clinical adverse events, physical examination and laboratory results. The evolution of liver fibrosis will be evaluated comparing the basal and end of treatment results of transient elastometry.

Not Provided
Interventional
Phase 2
Phase 3
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Liver Cirrhosis
  • Hepatitis C Virus
  • HIV Infection
Drug: Pegylated interferon alfa-2a and Ribavirin

Pegylated interferon alfa-2a (360 ug per week) plus oral Ribavirin (800 mg b.i.d.) for 48 or 72 weeks. The treatment will be discontinued for patients who did not achieve a reduction with respect to baseline of at least 0.5 log10 IU/ml in plasma RNA-HCV levels at week 4 or 2 log10 UI/ml at week 12 and will be considered as viral failures.

Duration: 48 weeks for patients reaching an undetectable plasma RNA_HCV at week12 and 72 weeks for those without a negative viremia at week 12 but a reduction of at least 2 log10 IU/ml in RNA-HCV levels.

Other Names:
  • Pegasys
  • Copegus
Experimental: PegIFN alfa-2a and Ribavirin
HIV-coinfected patients with compensated cirrhosis by hepatitis C virus, genotype 1 or 4.
Intervention: Drug: Pegylated interferon alfa-2a and Ribavirin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
December 2011
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age older than 18 years
  • HIV-infected patients with compensated liver cirrhosis by HCV genotype 1 or 4 without previous virological response(*) to a standard dose treatment of both drugs.
  • Women of child-bearing age: negative pregnancy test
  • Ability to understand and sign a written consent form

Exclusion Criteria:

  • HCV genotypes different to 1 or 4
  • Acute or chronic hepatitis B infection (positivity for hepatitis B surface antigen or plasma DNA) or other concomitant causes of liver disease
  • Pregnancy or breast feeding.
  • Decompensated liver disease at baseline.
  • Neutropenia <1000/uL, anemia <100 g/L or thrombocytopenia <20.000/uL.
  • Creatinine clearance < 50 mL/min.
  • Concomitant treatment with immunomodulators or zidovudine, didanosine or stavudine.
  • Organ or bone marrow transplantation
  • Current alcoholism or iv drug abuse. Methadone is allowed.
  • Current neoplasm and/or anti-tumor chemotherapy or immunomodulators
  • Psychosis or uncontrolled clinical depression
  • Auto-immune disease, including auto-immune hepatitis
  • History of significant cardiovascular disease (NYHA III-IV) including but not limited to uncontrolled hypertension, angina pectoris, myocardial infarction, coronary artery surgery and congestive heart failure.
  • Thyroid dysfunction.
  • Clinically significant retinal abnormalities
  • Inability to understand and sign a written consent form
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT01006031
HEPAVIR_IFN_2009
Yes
Antonio Rivero, Sociedad Andaluza de Enfermedades Infecciosas
Sociedad Andaluza de Enfermedades Infecciosas
Not Provided
Study Director: Luis F Lopez-Cortes, MD, PhD Instituto de Biomedicina de Sevilla. Hospitales Universitarios Virgen del Rocío
Principal Investigator: Luis F Lopez-Cortes, MD, PhD Instituto de Biomedicina de Sevilla. Hospitales Universitarios Virgen del Rocio
Principal Investigator: Antonio Rivero, MD, PhD Hospital Universitario Reina Sofia. Cordoba
Principal Investigator: Mª Jose Rios-Villegas, MD, PhD Hospital Universitario Viren MAcarena. Sevilla
Principal Investigator: Juan A. Pineda, MD, PhD Hospital Universitario de Valme. Sevilla
Sociedad Andaluza de Enfermedades Infecciosas
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP